Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

作者：Yoon‐Koo Kang, Masanori Terashima, Young‐Woo Kim, Narikazu Boku, Hyun Cheol Chung, Jen‐Shi Chen, Jiafu Ji, Ta-Sen Yeh, Li‐Tzong Chen, Min‐Hee Ryu, Jong Gwang Kim, Takeshi Omori, Sun Young Rha, Tae Yong Kim, Keun Won Ryu, Shinichi Sakuramoto, Yasunori Nishida, Norimasa Fukushima, Takanobu Yamada, Li‐Yuan Bai, Yoshinori Hirashima, Shunsuke Hagihara, Takashi Nakada, Mitsuru Sasako · 发表于：˜The œLancet. Gastroenterology & hepatology · 年份：2024 · DOI：10.1016/s2468-1253(24)00156-0 · 被引用次数：92 · 研究领域：Gastric Cancer Management and Outcomes、Cancer Immunotherapy and Biomarkers、Esophageal Cancer Research and Treatment